MSD Partners, China’s Panacea raise $200m SPAC to target biotech, life sciences sectors 2021-05-20T04:42:19-04:00May 20th, 2021| share this article! Panacea, a VC firm located in Shanghai, has become the latest investment firm to join the global SPAC fad. Read More share this article! Related Posts Japan, EU universities to partner on fostering chip and AI talent May 3rd, 2024 Vietnam’s Galaxy Education eyes up to $20m fundraising to expand footprint May 3rd, 2024 Sony looks to boost film assets with $26bn Paramount acquisition May 3rd, 2024 Soundwill pushes to revalue Causeway Bay site as demand declines May 3rd, 2024
